Share this article on:

Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy

Alphs, Larry; Nasrallah, Henry A.; Bossie, Cynthia A.; Fu, Dong-Jing; Gopal, Srihari; Hough, David; Turkoz, Ibrahim

International Clinical Psychopharmacology: July 2016 - Volume 31 - Issue 4 - p 202–209
doi: 10.1097/YIC.0000000000000125
Original Articles

Many patients with schizophrenia will relapse despite uninterrupted antipsychotic (AP) long-acting therapy (LAT). This exploratory analysis examined variables associated with relapse despite ensured adherence to LAT. This was a post-hoc exploratory analysis of a 1-year study of risperidone long-acting injection in patients with stable schizophrenia or schizoaffective disorder (NCT00297388; N=323). Patients were discontinued from previous oral APs and randomly assigned to biweekly intramuscular injections of risperidone long-acting injectable 50 (n=163) or 25 mg (n=161) for 52 weeks. Cox proportional hazards regression models examined variables putatively associated with relapse. A total of 59/323 (18.3%) patients relapsed over 12 months despite continuous AP LAT. Variables associated with the risk of relapse included illness duration (6.0% increase each year; P=0.0003) and country (Canada vs. USA, 4.7-fold risk increase; P=0.0008). When illness duration was further categorized as ≤5, 6–10, and >10 years, patients with an illness duration of >10 versus ≤5 years were at greatest risk of relapse (>10 vs. ≤5 years associated with a 4.4-fold increase in the risk of relapse; P=0.0181). Findings suggest that patients with more chronic illness have a greater risk of relapse despite ensured treatment adherence, supporting the need for early intervention to prevent the deleterious effects of chronicity.

aJanssen Scientific Affairs

bJanssen Research & Development, LLC, Titusville, New Jersey

cSaint Louis University School of Medicine, St Louis, Missouri, USA

Correspondence to Larry Alphs, MD, PhD, Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road – A32404, Titusville, NJ 08560, USA Tel: +1 609 730 3693; fax: +1 609 730 3125; e-mail: lalphs@its.jnj.com

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0/

Received October 29, 2015

Accepted February 10, 2016

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.